Gain Therapeutics, Inc.

The momentum for this stock is not very good. Gain Therapeutics, Inc. is not a good value stock. Gain Therapeutics, Inc. is a mediocre stock to choose.

News

HC Wainwright Reiterates "Buy" Rating for Gain Therapeutics (NASDAQ:GANX)

Ticker Report Gain Therapeutics (NASDAQ:GANX - Get Free Report)s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently...\n more…

Gain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by HC Wainwright

Zolmax Gain Therapeutics (NASDAQ:GANX - Get Free Report)s stock had its "buy" rating reissued by HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $8.00 price...\n more…

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ( Gain , or the Company ), a clinical-stage biotechnology company leading the discovery and development of...\n more…

Gain Therapeutics announces reuslts from Phase 1 study of GT-02287

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Globe Newswire Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson's Disease, on Track to Initiate Phase 1b Trial in Patients in Q4 2024...\n more…

Gain Therapeutics (NASDAQ:GANX) Given Outperform Rating at Oppenheimer

Ticker Report Oppenheimer reissued their outperform rating on shares of Gain Therapeutics (NASDAQ:GANX - Free Report) in a research report sent to investors on Wednesday morning, MarketBeat.com reports. The firm...\n more…